Want to see BDRX full AI Analyst Report?
Top Page
Biodexa Pharmaceuticals
(NASDAQ:BDRX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-9.09% Downside)
Action:Reiterated
Date:07/22/26
Overall score is weighed down primarily by weak financial performance (zero revenue, ongoing losses, and negative free cash flow) and very bearish technical momentum (price below key moving averages with depressed RSI/stochastic). A low-debt balance sheet and improved (but still negative) operating cash flow provide only partial support, while valuation is limited by negative earnings and no dividend yield data.
Positive Factors
Balance Sheet Strength
Very low debt and rising equity/assets create a durable financial cushion that reduces insolvency risk and preserves optionality. This balance-sheet strength supports continued R&D investment, improves ability to access capital or credit when needed, and underpins the clinical-stage strategy over coming quarters.
Negative Factors
No Product Revenue
The company remains pre-commercial with no product revenue, leaving its long-term viability dependent on successful clinical outcomes and external funding. Absent commercialization, operations hinge on trial results and financing cadence rather than recurring business economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Very low debt and rising equity/assets create a durable financial cushion that reduces insolvency risk and preserves optionality. This balance-sheet strength supports continued R&D investment, improves ability to access capital or credit when needed, and underpins the clinical-stage strategy over coming quarters.
Read all positive factors
Biodexa Pharmaceuticals (BDRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.68B
Dividend YieldN/A
Average Volume (3M)260.97K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue GrowthN/A
EPS Growth88.07%
CountryUS
Employees11
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-536.25
Shares Outstanding828,923
10 Day Avg. Volume685,915
30 Day Avg. Volume260,967
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.03
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$7.66K
Biodexa Pharmaceuticals Business Overview & Revenue Model
Company Description
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as ...
How the Company Makes Money
null...
Biodexa Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 381.00K | 699.00K | 578.00K |
| Gross Profit | -184.86K | -5.44M | -3.69M | -4.41M | -4.08M |
| EBITDA | -8.08M | -9.08M | -7.16M | -8.26M | -5.66M |
| Net Income | -6.24M | -5.73M | -7.08M | -7.66M | -5.46M |
Balance Sheet | |||||
| Total Assets | 18.15M | 14.78M | 10.54M | 5.53M | 12.91M |
| Cash, Cash Equivalents and Short-Term Investments | 8.52M | 1.67M | 5.97M | 2.84M | 10.06M |
| Total Debt | 60.89K | 727.00K | 464.00K | 624.00K | 766.00K |
| Total Liabilities | 6.76M | 6.46M | 5.86M | 2.36M | 2.46M |
| Stockholders Equity | 11.38M | 8.32M | 4.68M | 3.16M | 10.45M |
Cash Flow | |||||
| Free Cash Flow | -5.40M | -13.04M | -7.09M | -7.11M | -6.33M |
| Operating Cash Flow | -5.39M | -12.26M | -6.83M | -7.05M | -6.01M |
| Investing Cash Flow | -658.25K | -598.00K | -265.00K | -220.00K | -278.00K |
| Financing Cash Flow | 12.77M | 8.56M | 10.23M | 47.00K | 8.80M |
Biodexa Pharmaceuticals Technical Analysis
Negative
1.65
Price Trends
2.67
Negative
3.15
Negative
10.77
Negative
Market Momentum
-0.35
Positive
19.57
Positive
4.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDRX, the sentiment is Negative. The current price of 1.65 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.67, and below the 200-day MA of 10.77, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 19.57 is Positive, neither overbought nor oversold. The STOCH value of 4.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDRX.
Biodexa Pharmaceuticals Risk Analysis
Biodexa Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Biodexa Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Geopolitical risks could result in increased market volatility and uncertainty, which could negatively impact our business, financial condition and results of operation. Q4, 2023
Biodexa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | $4.97M | >-0.01 | -72.72% | ― | -34.06% | 79.61% | |
49 Neutral | $7.09M | -0.20 | -238.69% | ― | ― | 99.30% | |
43 Neutral | $163.07M | -0.20 | -1028.81% | ― | ― | 61.43% | |
42 Neutral | $6.68B | >-0.01 | -55.81% | ― | ― | 88.07% | |
42 Neutral | $5.27M | -0.06 | -220.99% | ― | ― | 82.92% |
* General Sector Average
BDRX
Biodexa Pharmaceuticals
1.32
-33.58
-96.22%
INDP
Indaptus Therapeutics
1.29
-6.01
-82.33%
INM
InMed Pharmaceuticals
1.47
-0.90
-37.97%
ENVB
Enveric Biosciences
1.57
-12.23
-88.62%
CNSP
CNS Pharmaceuticals
5.82
-1.69
-22.54%
Biodexa Pharmaceuticals Corporate Events
Biodexa Pharmaceuticals Restructures Share Capital and Boosts Issuance Capacity After July 29 General Meeting
Jul 29, 2026
On July 29, 2026, Biodexa Pharmaceuticals’ shareholders approved all resolutions at a general meeting, including a one-for-10,000 reorganization of its ordinary shares and a change in the ratio of ordinary shares to American Depositary Share...
Biodexa Pharmaceuticals Calls July 29 General Meeting to Overhaul Share Capital Structure
Jul 9, 2026
On July 8, 2026, Biodexa distributed a notice convening a general meeting for July 29, 2026, in Cardiff, where shareholders will vote on a sweeping share capital reorganisation and related governance changes. The proposed measures include consolid...
Biodexa Pharmaceuticals Investors Reject Key Resolutions at June 30 AGM
Jun 30, 2026
On June 30, 2026, Biodexa Pharmaceuticals reported the results of its rescheduled Annual General Meeting, where ordinary resolutions 1 through 7 were approved with shareholder support ranging from 73% to 94%. However, ordinary resolution 8 and spe...
Biodexa Raises $3.5 Million via Registered Offering, Private Placement and Warrant Inducement
Jun 30, 2026
On June 29–30, 2026, Biodexa Pharmaceuticals PLC priced a series of equity financings and warrant transactions, including a $0.8 million registered direct offering of 282,952 American depositary shares or pre-funded warrants at $2.85 per ADS...
Biodexa Pharmaceuticals Adjourns AGM for Lack of Quorum, Reschedules to June 30
Jun 17, 2026
On June 17, 2026, Biodexa Pharmaceuticals announced that its Annual General Meeting scheduled for that day in Cardiff was adjourned due to a lack of quorum, preventing shareholders from conducting planned corporate business. In line with its artic...
Biodexa Pharmaceuticals Proposes Major Share Capital Reorganization Ahead of June AGM
May 14, 2026
On May 14, 2026, Biodexa Pharmaceuticals issued its 2025 Annual Report and convened shareholders for an Annual General Meeting scheduled on June 17, 2026 in Cardiff. The company also circulated AGM proxy forms to holders of ordinary shares and Ame...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.